Clifford Chance
China's blueprint for its pharmaceutical sector
14 October 2019
China has stepped up its legislative reform of the pharmaceutical sector to drive down prices, improve access to new drugs and foster generic competition with brand name drugs. These policies have had a wide-ranging impact on the industry and led many drug companies to restructure their China-based portfolio of drugs, sales model and investment strategy, creating new opportunities for international and domestic players alike.
Clifford Chance experts assess the changing regulatory landscape as the Chinese government puts quality and affordability at the centre of its healthcare policy agenda.
